• In August 2026, Stoke Therapeutics reported second‑quarter 2026 results showing sales of US$9.33 million versus US$13.82 million a year earlier, alongside a net loss of US$61.62 million and basic and diluted loss per share of US$0.93 from continuing operations, compared with US$23.48 million and US$0.40 a year ago.
• For the first half of 2026, sales dropped to US$15.55 million from a very large prior‑year figure, while the company swung from net income of US$89.40 million to a net loss of US$111.62 million, and simultaneously filed a US$57.72 million shelf registration for 2,000,000 common shares linked to an ESOP offering, highlighting both operating pressure and potential future dilution.
• Against this backdrop of weaker revenues and a new US$57.72 million shelf registration, we’ll examine how these developments reshape Stoke’s investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Stoke Therapeutics Investment Narrative Recap

To own Stoke Therapeutics, you need to believe that zorevunersen’s late‑stage Dravet program and the broader antisense platform can ultimately justify today’s heavy investment and losses. The latest quarter’s sharp swing back to a net loss and lower sales underlines how dependent the equity story is on clinical and regulatory progress, rather than current earnings, and it keeps funding risk and potential dilution among the most important near term concerns.

The most relevant development alongside these results is the US$57.72 million shelf registration for 2,000,000 common shares tied to an ESOP offering. Coming immediately after a first half net loss of US$111.62 million, this filing matters for anyone focused on the EMPEROR Phase III and NDA timelines, because it reminds shareholders that Stoke’s path through these catalysts could involve further equity issuance and ownership dilution.

Yet beneath the promise of disease modifying antisense drugs, investors should be aware that concentrated rare disease exposure and rising dilution risk could...

Stoke Therapeutics' narrative projects $177.8 million revenue and $33.6 million earnings by 2029. This requires 77.0% yearly revenue growth and a $203.4 million earnings increase from -$169.8 million today.

Uncover how Stoke Therapeutics' forecasts yield a $45.10 fair value, a 38% upside to its current price.

Exploring Other Perspectives

Before this setback, the most optimistic analysts were modeling revenue to compound around 100 percent a year and earnings above US$50 million, while also assuming Stoke could fund EMPEROR without near term dilution, so this weaker quarter and new shelf registration may prompt you to rethink how confident you are in those best case scenarios.

Explore 4 other fair value estimates on Stoke Therapeutics - why the stock might be worth over 10x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Stoke Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stoke Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stoke Therapeutics' overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.